OIG raises concerns about accelerated approval pathway
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesNorth AmericaPharmaceuticalsProduct Lifecycle